Disease Education
What is RLT
[68Ga]Ga-PSMA-11 and [177Lu]Lu-PSMA-617 Mechanism of Action
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data.
Explore Clinical Trials
Explore Clinical Trials
NCT04720157
PSMAddition
An open-label, randomized, Phase III study comparing [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in combination with standard of care (SoC) vs SoC alone in adult male patients with mHSPC
NCT04838626
GuideView
Phase II/III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging for the detection of PSMA-positive tumors using histopathology as a standard of truth
NCT03872778
NeoRay
A Phase I/IIa, open-label, multicenter study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and antitumor activity of [177Lu]Lu-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)
